RRBM-RRBSO was only the most effective risk-reducing strategy in patients with TN breast cancer under 40 years in stage I with the BRCA1 pathogenic variant and in patients aged 40-49 years with the BRCA1 pathogenic variant in exons 1-10. This evidence concerns the gene BRCA1 and breast carcinoma.